Lixte Biotechnology (LIXT) Competitors $1.26 -0.03 (-2.02%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIXT vs. BCTX, LPTX, BIVI, MIRA, GLYC, ABVC, NRSN, COCP, PHIO, and INABShould you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include BriaCell Therapeutics (BCTX), Leap Therapeutics (LPTX), BioVie (BIVI), MIRA Pharmaceuticals (MIRA), GlycoMimetics (GLYC), ABVC BioPharma (ABVC), NeuroSense Therapeutics (NRSN), Cocrystal Pharma (COCP), Phio Pharmaceuticals (PHIO), and IN8bio (INAB). These companies are all part of the "pharmaceutical products" industry. Lixte Biotechnology vs. BriaCell Therapeutics Leap Therapeutics BioVie MIRA Pharmaceuticals GlycoMimetics ABVC BioPharma NeuroSense Therapeutics Cocrystal Pharma Phio Pharmaceuticals IN8bio BriaCell Therapeutics (NASDAQ:BCTX) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment. Does the media refer more to BCTX or LIXT? In the previous week, BriaCell Therapeutics had 11 more articles in the media than Lixte Biotechnology. MarketBeat recorded 12 mentions for BriaCell Therapeutics and 1 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 1.87 beat BriaCell Therapeutics' score of -0.13 indicating that Lixte Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment BriaCell Therapeutics Neutral Lixte Biotechnology Very Positive Do insiders and institutionals hold more shares of BCTX or LIXT? 15.4% of BriaCell Therapeutics shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 5.7% of BriaCell Therapeutics shares are held by company insiders. Comparatively, 14.8% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is BCTX or LIXT more profitable? BriaCell Therapeutics' return on equity of 0.00% beat Lixte Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets BriaCell TherapeuticsN/A N/A -191.19% Lixte Biotechnology N/A -5,562.77%-130.48% Which has more risk & volatility, BCTX or LIXT? BriaCell Therapeutics has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Do analysts prefer BCTX or LIXT? BriaCell Therapeutics currently has a consensus target price of $32.00, suggesting a potential upside of 617.49%. Given BriaCell Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe BriaCell Therapeutics is more favorable than Lixte Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BriaCell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Lixte Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings & valuation, BCTX or LIXT? BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Lixte Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBriaCell TherapeuticsN/AN/A-$4.79M-$5.03-0.89Lixte BiotechnologyN/AN/A-$5.09M-$1.59-0.79 Does the MarketBeat Community prefer BCTX or LIXT? BriaCell Therapeutics received 13 more outperform votes than Lixte Biotechnology when rated by MarketBeat users. CompanyUnderperformOutperformBriaCell TherapeuticsOutperform Votes13100.00% Underperform VotesNo VotesLixte BiotechnologyN/AN/A SummaryBriaCell Therapeutics beats Lixte Biotechnology on 10 of the 14 factors compared between the two stocks. Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIXT vs. The Competition Export to ExcelMetricLixte BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.97M$6.90B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E Ratio-0.737.4522.4218.48Price / SalesN/A242.72394.10103.91Price / CashN/A65.8538.1834.62Price / Book5.736.516.774.25Net Income-$5.09M$143.21M$3.22B$248.23M7 Day Performance-3.08%3.97%3.26%3.29%1 Month Performance-0.79%0.37%0.02%2.42%1 Year Performance-56.40%2.60%18.01%5.54% Lixte Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIXTLixte Biotechnology1.095 of 5 stars$1.26-2.0%N/A-56.4%$3.97MN/A-0.734Upcoming EarningsPositive NewsBCTXBriaCell Therapeutics1.5891 of 5 stars$4.19-2.3%$32.00+663.7%-86.3%$15.54MN/A-0.318News CoverageLPTXLeap Therapeutics2.4498 of 5 stars$0.36-1.0%$4.92+1,267.3%-86.5%$14.84MN/A-0.1940Gap UpBIVIBioVie2.7204 of 5 stars$0.79-5.6%$3.00+277.8%+66.9%$14.65MN/A-0.0810Short Interest ↓News CoverageMIRAMIRA Pharmaceuticals2.6026 of 5 stars$0.87-7.9%$14.00+1,518.5%+36.5%$14.54MN/A-1.542Short Interest ↓GLYCGlycoMimetics2.1306 of 5 stars$0.22-1.3%N/A-86.0%$14.19M$10,000.00-0.3750Short Interest ↓Gap UpABVCABVC BioPharma1.0933 of 5 stars$0.87+2.1%N/A-15.2%$13.77M$509,788.00-1.0130Earnings ReportPositive NewsNRSNNeuroSense Therapeutics1.1238 of 5 stars$1.00-3.2%N/A-27.4%$13.67MN/A-1.5610Short Interest ↓COCPCocrystal Pharma2.489 of 5 stars$1.34+1.9%$7.00+424.2%-4.4%$13.58MN/A-0.7210PHIOPhio Pharmaceuticals2.5676 of 5 stars$2.83+3.7%$4.00+41.3%-69.4%$13.52MN/A-0.2610Upcoming EarningsINABIN8bio3.6014 of 5 stars$0.17+3.3%$6.00+3,510.1%-83.4%$13.51MN/A-0.2220Upcoming EarningsShort Interest ↓ Related Companies and Tools Related Companies BCTX Alternatives LPTX Alternatives BIVI Alternatives MIRA Alternatives GLYC Alternatives ABVC Alternatives NRSN Alternatives COCP Alternatives PHIO Alternatives INAB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIXT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LIXT Stock Free LIXT Stock Alerts